Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 1999

View Archived Issues

Avigen reports advances in gene therapy for hemophilia A

Biogen provides update on top three proprietary products

Recent significant events at P&U summarized

Elan plans clinical trials for AD treatment

EpiGenesis focuses on development of new class of respiratory agents

Company Profile: Actinova

Inhibitors of TNF-alpha production/release in early development at Sumitomo

Meiji Milk Products reveals new antiangiogenic agents

New imidazole compounds from Taisho/Sagami inhibit PDE1

Preparation and activity of apoptosis inducers disclosed by Takara Shuzo

Bristol-Myers Squibb begins phase II testing of inlicensed quinolone

Photogen teams up with Akorn to advance development of PH-10

Potent, broad-spectrum, orally bioavailable carbapenems designed by Sankyo

Integrin alphavbeta3 antagonist findings presented by Genentech team at AHA

SUN-N5030 emerges as potent neuroprotectant from new class of dual Na+/Ca2+ channel blockers

Preclinical data reported at ASN support utility of OP-1 in treating renal disease

Mixed AMPA and glycine-site NMDA antagonist with i.v./i.p. anticonvulsant activity

Positive findings of ACTION I study presented at ASN

Genetronics and Boehringer Ingelheim enter collaborative gene therapy agreement

Phase II data support further study of VX-497 for hepatitis C

United Therapeutics completes enrollment in phase III pulmonary hypertension trial

Major U.K. biopharmaceutical company merger announced

Xenova's lead drug candidates enter phase II trials during Q3 1999

AASLD presentations support feasibility of ribozyme therapy in HCV

SDZ-RAD inhibits HBV antigen production, transcription, unlike other immunosuppressants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...